广州市香雪制药股份有限公司（以下简称"公司"）第九届监事会第二十二 次会议于 2025 年 10 月 27 日在公司本部会议室以现场方式召开，会议通知已于 2025 年 10 月 17 日以邮件等方式送达了全体监事，会议应到监事三名，实到监 事三名，会议由监事会主席黄伟华女士主持。本次会议的召开、议事方式和表决 程序符合《中华人民共和国公司法》和《公司章程》对召开监事会的规定，与会 监事认真审议会议议案，经表决方式通过并作出如下决议： 一、审议通过了《关于<2025 年第三季度报告全文>的议案》 证券代码：300147 证券简称：ST 香雪 公告编号：2025-049 广州市香雪制药股份有限公司 第九届监事会第二十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 广州市香雪制药股份有限公司监事会 2025 年 10 月 28 日 监事会认为，公司董事会编制、审核的《2025 年第三季度报告》，程序符合 法律、行政法规的规定，报告内容真实、准确、完整地反映了公司的实际情况， 不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容详见巨潮 ...

公司《2025 年第三季度报告》的编制程序符合法律、行政法规的规定，报 告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏。具体内容详见巨潮网披露的《2025 年第三季度报告》。 证券代码：300147 证券简称：ST 香雪 公告编号：2025-048 广州市香雪制药股份有限公司 第九届董事会第三十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会第三十一 次会议于 2025 年 10 月 27 日在公司本部会议室以现场结合通讯方式召开，会议 通知已于 2025 年 10 月 17 日以邮件等方式送达了全体董事。会议应参加董事六 名，实际参加董事六名，独立董事吴杰先生、周庆权先生、陶剑虹女士以通讯方 式出席，无委托出席的情况，公司监事和高级管理人员等相关人员列席了本次会 议，会议由董事长王永辉先生主持。本次会议的召开、议事方式和表决程序符合 《中华人民共和国公司法》和《公司章程》对召开董事会的规定，经表决方式通 过并作出如下决议： 一、审议通过了《 ...

Financial Performance - Q3 2025 revenue was CNY 327,919,419.86, a decrease of 24.96% year-over-year[4] - Net loss attributable to shareholders was CNY -128,027,968.87, down 55.04% compared to the same period last year[4] - Total operating revenue decreased to ¥1,145,913,241.87 from ¥1,533,560,038.60, representing a decline of approximately 25.3% year-over-year[17] - Net profit for the period was a loss of ¥339,087,946.76, compared to a loss of ¥196,889,583.22 in the previous period, indicating a worsening of approximately 72.0%[18] - The company reported a total comprehensive loss of ¥339,447,903.88, compared to a loss of ¥196,954,831.78 in the previous period, indicating an increase in losses of approximately 72.2%[18] - Basic and diluted earnings per share were both reported at -¥0.55, compared to -¥0.33 in the previous period, reflecting a decline in performance[18] Cash Flow and Liquidity - Cash flow from operating activities increased by 175.41% year-to-date, totaling CNY 27,270,008.25[4] - Operating cash flow generated was ¥27,270,008.25, a significant improvement from a negative cash flow of ¥36,164,599.65 in the prior period[19] - Cash and cash equivalents at the end of the period totaled ¥119,423,134.37, compared to ¥65,733,446.88 at the end of the previous period, showing an increase of approximately 81.5%[20] - The company experienced a net cash outflow from investing activities of ¥13,391,083.96, compared to a net inflow of ¥27,951,254.29 in the prior period[19] - Total cash inflow from financing activities was ¥98,243,361.02, compared to ¥38,496,807.35 in the previous period, indicating an increase of approximately 155.5%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,364,569,652.39, a decrease of 1.78% from the previous year[5] - The company's total liabilities increased to ¥6,265,814,683.02 from ¥6,059,565,986.39, indicating a rise in financial obligations[15] - The company's inventory decreased to ¥298,118,335.24 from ¥340,919,525.62, a decline of approximately 12.5%[14] - The total equity attributable to the parent company decreased to ¥692,637,257.30 from ¥1,054,899,213.92, a significant drop of about 34.3%[16] - The company reported a net loss in retained earnings, which worsened to -¥2,198,160,362.47 from -¥1,836,258,362.97[16] - The non-current liabilities decreased significantly to ¥217,539,784.45 from ¥677,549,244.88, indicating a reduction in long-term financial commitments[15] - The company’s short-term borrowings slightly decreased to ¥1,344,464,472.53 from ¥1,355,145,836.75, a reduction of about 0.8%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 34,981[10] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 22.59% of the shares, with 144,524,872 shares pledged[10] Government Support and Accounting Changes - The company received government subsidies totaling CNY 2,132,592.26 during the reporting period[6] - The new accounting standards will be implemented starting from 2025[22] Other Financial Metrics - The weighted average return on equity was -16.49%, a decrease of 11.77% year-over-year[4] - The company reported a significant increase in inventory impairment losses, up 1620.76% compared to the previous period[9] - Research and development expenses were ¥48,816,040.21, down from ¥53,060,653.17, reflecting a decrease of about 8.5% year-over-year[17] Audit Status - The third quarter financial report of the company has not been audited[21] Financial Restructuring - The company received a court decision extending its pre-restructuring period until January 11, 2026, indicating ongoing financial restructuring efforts[13]

Core Viewpoint - The company is preparing to enter the confirmatory clinical trial phase for its drug TAEST16001, which has already received approval from the CDE and has undergone expert discussions, indicating readiness for patient enrollment [1] Group 1: Clinical Trial Progress - The company has confirmed that TAEST16001 is set to enter the confirmatory clinical trial phase [1] - The chairman previously mentioned the goal of entering this phase soon, highlighting the urgency of the timeline [1] - The company is aware of the importance of enrollment progress for pipeline advancement, especially in light of ADAP's recent delisting due to insufficient R&D efficiency [1] Group 2: Information Disclosure - The company will disclose the progress of new drug development according to information disclosure rules and actual circumstances through official announcements [1] - Investors are encouraged to pay attention to the company's announcements for updates on enrollment timelines and current progress [1]

Core Viewpoint - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (referred to as "Xiangxue Pharmaceutical") has received an extension for its pre-restructuring period until January 11, 2026, marking the second extension of this period, with ongoing uncertainty regarding its entry into formal restructuring procedures [1][3]. Group 1: Pre-restructuring Process - On January 27, 2023, Xiangxue Pharmaceutical was notified by creditor Guangdong Jinglong Construction Group Co., Ltd. about its inability to repay debts, leading to a request for pre-restructuring [2]. - The Guangzhou Intermediate People's Court held a hearing on February 12, 2023, regarding the pre-restructuring of Xiangxue Pharmaceutical [2]. - The court approved the pre-restructuring on April 11, 2023, designating temporary management and extending the pre-restructuring period multiple times, with the latest extension to October 11, 2025 [2]. Group 2: Financial Performance and Debt Situation - Xiangxue Pharmaceutical has faced significant financial losses, with net profits declining from over 66 million yuan in 2016 to a loss of 677 million yuan in 2021, attributed to increased market competition and insufficient marketing efforts [4]. - The company reported losses of 530 million yuan, 389 million yuan, and 859 million yuan for the years 2022 to 2024, respectively, with a revenue drop of 25.40% in the first half of this year [4]. - As of the end of 2024, the total liabilities of Xiangxue Pharmaceutical reached 6.06 billion yuan, with a debt-to-asset ratio of 80.82% [5]. Group 3: Legal and Regulatory Issues - In August 2023, Xiangxue Pharmaceutical and its actual controller were penalized for information disclosure violations, resulting in fines totaling 16 million yuan [6][7]. - The company has been involved in numerous lawsuits, with the total amount in litigation reaching approximately 223 million yuan, which is 21.18% of its latest audited net assets [5]. - The company has warned that if the court accepts the restructuring application, it may face delisting risks if the restructuring fails [8].

Group 1 - The company did not participate in the 2025 European Society for Medical Oncology (ESMO) conference [1]

Core Viewpoint - ST Xiangxue (300147.SZ) has received a decision from the Guangzhou Intermediate People's Court, extending its pre-restructuring period until January 11, 2026 [1] Group 1 - The Guangzhou Intermediate People's Court has approved the extension of ST Xiangxue's pre-restructuring period [1]

证券代码:300147 证券简称:ST 香雪 公告编号:2025—047 广州市香雪制药股份有限公司 关于收到延长预重整期间决定书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、广州中院延长公司预重整期间情况 2025 年 10 月 20 日，广州市香雪制药股份有限公司（以下简称"公司"） 收到广州市中级人民法院（以下简称"广州中院"）送达的（2025）粤 01 破申 54-2 号《决定书》，主要内容如下： 经审查，本院同意广州市香雪制药股份有限公司预重整期间延长至 2026 年 1 月 11 日。 二、公司预重整进展情况 1、2025 年 1 月 27 日，公司收到债权人广东景龙建设集团有限公司（以下 简称"景龙建设"）送达的《告知函》，其以公司未履行生效法律文书、不能清 偿到期债务，明显缺乏清偿能力，但具有重整价值及重整的可行性为由，向广州 中院申请对公司进行预重整。具体内容详见公司于 2025 年 2 月 6 日在巨潮网披 露的《关于被债权人申请预重整的提示性公告》（公告编号：2025-002）。 2025 年 2 月 12 日，广州中院就公 ...

Core Insights - The Chinese medicine sector experienced a slight decline of 0.28% on September 30, with ST Xiangxue leading the losses [1][2] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Xinbang Pharmaceutical (002390) with a closing price of 3.80, up 10.14% and a trading volume of 974,400 shares, totaling 361 million yuan [1] - Wanbangde (002082) closed at 66.11, up 10.00% with a trading volume of 216,600 shares, totaling 252 million yuan [1] - Other companies with positive performance included: - Jinhua Co. (600080) up 2.91% [1] - Zhongsheng Pharmaceutical (002317) up 1.83% [1] Fund Flow Analysis - The Chinese medicine sector saw a net outflow of 478 million yuan from institutional investors, while retail investors contributed a net inflow of 395 million yuan [2][3] - Key stocks with significant fund flow included: - Xinbang Pharmaceutical (002390) with a net inflow of 135 million yuan from institutional investors [3] - Zhongsheng Pharmaceutical (002317) with a net inflow of 57.69 million yuan [3] - Wanbangde (002082) with a net inflow of 53.26 million yuan [3]

证券代码：300147 证券简称：ST 香雪 公告编号：2025-045 广州市香雪制药股份有限公司 第九届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 表决结果：同意 6 票、反对 0 票、弃权 0 票。 特此公告。 广州市香雪制药股份有限公司董事会 2025 年 9 月 30 日 审议通过了《关于聘任董事会秘书的议案》 公司董事会于近日收到公司董事、董事会秘书徐力先生的书面辞职报告，徐 力先生因个人原因，申请辞去公司董事会秘书职务，辞去上述职务后，徐力先生 仍在公司担任董事职务。 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》及《公司章程》的相关规定，公司董事会同意聘任向进先生 担任公司董事会秘书，任期自本次董事会审议通过之日起至第九届董事会届满之 日止（目前公司第九届董事会已届满，换届选举工作尚在筹备中，为保证公司董 事会工作的连续性和稳定性，公司第九届董事会将延期换届，本届董事会各专门 委员会、高级管理人员的任期也将相应顺延）。 本议案已经公司董事会提名委员会审议通过。 具体内容 ...